Class-Action Suit Alleges Medtronic’s Rosy Forecast For MiniMed780G Misled Investors
Executive Summary
The lawsuit says that Medtronic continued to predict that the new insulin pump would be FDA-approved shortly, even as other regulatory issues and recalls in the diabetes division made that less likely.
You may also be interested in...
Medtronic’s 780G – Finally! – Gets FDA Approval
Earlier than expected, but still after a more than three year wait, the company has obtained FDA approval for its flagship insulin delivery system.
Talking ATTD, 780G, Rumors And Missteps With Medtronic’s Diabetes Leaders
Medtech Insight spoke to the president of Medtronic’s diabetes business, Que Dallara, as well as two of the company’s medical affairs directors, about the company’s recently published data, and the timeline for the US launch of its 780G system.
Tandem’s CSO Speaks On Insulin Pump Development And Its Challenges
Insulin pumps have lagged behind continuous glucose monitors in terms of market penetration due to their cost and the complex regulatory framework that surrounds them. Elizabeth Gasser, chief strategy officer at Tandem Diabetes spoke to Medtech Insight about these challenges and how the company is taking a slightly different approach to pumps.